FY2025 · ended Dec 31, 2025 · Revenue $4.27B, +4.9% YoY · Filed Feb 24, 2026
Jazz Pharmaceuticals plc (JAZZ) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $4.3 billion and a net loss of $356.1 million. Free cash flow was $1.3 billion. As of Sep 30, 2026 it held $2.0 billion in cash and investments and $5.6 billion in total debt.
Revenue (TTM)
$4.72B
+13.5% vs year-ago TTM
Net income (TTM)
$205.95M
+155.9% vs year-ago TTM
Operating cash flow (TTM)
$1.69B
+21.6% vs year-ago TTM
Free cash flow (TTM)
$1.62B
+21.3% vs year-ago TTM
EPS (TTM)
$3.09
+151.3% vs year-ago TTM
Dividend per share
None
Shares outstanding
62.74M
+1.9% vs prior year
Net cash
$-3.59B
as of Sep 30, 2026
Operating margin
9.0%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- JAZZ (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Ireland
- Headquarters
- Dublin
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1232524
- Former names
- JAZZ PHARMACEUTICALS INC (until Jan 18, 2012)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $4.3B | $4.1B | $3.8B | $3.7B | $3.1B |
| Operating income | -$430.2M | $716.6M | $578.6M | -$65.5M | $170.3M |
| Net income | -$356.1M | $560.1M | $414.8M | -$224.1M | -$329.7M |
| Diluted EPS | -$5.84 | $8.65 | $6.10 | -$3.58 | -$5.52 |
| Operating cash flow | $1.4B | $1.4B | $1.1B | $1.3B | $778.5M |
| Free cash flow | $1.3B | $1.4B | $1.1B | $1.2B | $750.9M |
| Total assets | $11.7B | $12.0B | $11.4B | $10.8B | $12.3B |
| Stockholders' equity | $4.3B | $4.1B | $3.7B | $3.1B | $4.0B |
| Cash and investments | $3.8B | $5.4B | $3.1B | $1.8B | $1.2B |
| Total debt | $5.4B | $6.2B | $5.8B | $5.8B | $6.2B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 2, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 2, 2026 | Nov 2, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 26, 2026 | Oct 26, 2026 |
| 8-K |
Current report
Officer or director change
|
Oct 9, 2026 | Oct 6, 2026 |
| 8-K |
Current report
Material agreement, New debt
|
Sep 23, 2026 | Sep 23, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 15, 2026 | Sep 15, 2026 |
All 1000 Jazz Pharmaceuticals plc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.